NAMD Submits Comments on Congressional Request for Information on Dually Eligible Members
NAMD highlights strategies to improve systems of care for dually eligible members.
Medicare Must Not Cost Shift Alzheimer’s Care to Medicaid
NAMD explains the serious cost implications of Medicare’s coverage decision on the Alzheimer’s drug Aduhelm for state Medicaid programs.
Author
- Jack Rollins, Director of Federal Policy
Focus Areas
Program Stream
In a controversial decision, the Food and Drug Administration recently approved Aduhelm, a drug intended to treat Alzheimer’s disease. Now Medicare must decide if it will cover the drug, and its decision has significant cost implications for state Medicaid programs. If Medicare does not cover it and Medicaid becomes the primary source of coverage, NAMD estimates Medicaid spending for Aduhelm could increase by 250 percent or more. In this blog, NAMD’s Director of Federal Policy explains these potential implications.
Related resources
Prescription Drug Spending: What’s Coming Next for Medicaid and How Can States Prepare?
Experts at the NAMD Fall Conference discussed challenges with high-cost drugs.
NAMD Comments on Proposed Medicare Special Enrollment Periods and Savings Program Changes
On June 27, NAMD submitted comments on the Centers for Medicare and Medicaid Services' proposed rule, Implementing Certain...
Stay Informed
Drop us your email and we’ll keep you up-to-date on Medicaid issues.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.